Such type of sympatholytic effect could be instrumental in the SGLT2 inhibitor-mediated anticancer effects since a very recent report demonstrated that suppressing β2-adrenergic signaling in the tumor microenvironment potentiated the efficacy of doxorubicin in a triple-negative breast cancer model [56]. This evidence concerns the gene SLC5A2 and neoplasm.